Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Smitha Menon MD

Associate Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Hematology and Oncology - Medicine
Program: Bone Marrow Transplant

Member of the Cancer Center


Publications

  • Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC. (Lin JJ, Zhu VW, Schoenfeld AJ, Yeap BY, Saxena A, Ferris LA, Dagogo-Jack I, Farago AF, Taber A, Traynor A, Menon S, Gainor JF, Lennerz JK, Plodkowski AJ, Digumarthy SR, Ou SI, Shaw AT, Riely GJ) J Thorac Oncol 2018 Oct;13(10):1530-1538 PMID: 29935304 06/24/2018    
  • Liquid Biopsies and Cancer Immunotherapy. (Thompson JR, Menon SP) Cancer J 2018 Mar/Apr;24(2):78-83 PMID: 29601334 03/31/2018       1 Citations
  • Advances in Cancer Immunotherapy in Solid Tumors. (Menon S, Shin S, Dy G) Cancers (Basel) 2016 Nov 24;8(12) PMID: 27886124 PMCID: PMC5187504 11/26/2016    
  • Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options. (Desai A, Menon SP, Dy GK) Cancer Biol Med 2016 Mar;13(1):77-86 PMID: 27144064 PMCID: PMC4850130 05/05/2016    
  • Should Vital Signs Be Routinely Obtained Prior to Intravenous Chemotherapy? Results From a 2-Center Study. (Menon S, Foster NR, Looker S, Sorgatz K, Kasi PM, McWilliams RR, Jatoi A) Cancer Control 2015 Oct;22(4):515-9 PMID: 26678980 12/19/2015    
  • Maximizing Time with the Patient: the Creative Concept of a Physician Scribe. (Menon SP) Curr Oncol Rep 2015 Dec;17(12):59 PMID: 26475774 10/18/2015       2 Citations
  • Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. (Wolf SL, Qin R, Menon SP, Rowland KM Jr, Thomas S, Delaune R, Christian D, Pajon ER Jr, Satele DV, Berenberg JL, Loprinzi CL, North Central Cancer Treatment Group Study N05C5) J Clin Oncol 2010 Dec 10;28(35):5182-7 PMID: 21060036 PMCID: PMC3020691 11/10/2010       32 Citations
  • Adjuvant chemotherapy for resected stage II and III colon cancer: comparison of two widely used prognostic calculators. (Bardia A, Loprinzi C, Grothey A, Nelson G, Alberts S, Menon S, Thome S, Gill S, Sargent D) Semin Oncol 2010 Feb;37(1):39-46 PMID: 20172363 PMCID: PMC2864519 02/23/2010       17 Citations
  • Thromboembolic events with lenalidomide-based therapy for multiple myeloma. (Menon SP, Rajkumar SV, Lacy M, Falco P, Palumbo A) Cancer 2008 Apr 01;112(7):1522-8 PMID: 18278812 PMCID: PMC2614405 02/19/2008       64 Citations
  • Lenalidomide-associated hypothyroidism. (Menon S, Habermann T, Witzig T) Leuk Lymphoma 2007 Dec;48(12):2465-7 PMID: 18067027 12/11/2007       13 Citations
  • End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. (Sargent DJ, Patiyil S, Yothers G, Haller DG, Gray R, Benedetti J, Buyse M, Labianca R, Seitz JF, O'Callaghan CJ, Francini G, Grothey A, O'Connell M, Catalano PJ, Kerr D, Green E, Wieand HS, Goldberg RM, de Gramont A, ACCENT Group) J Clin Oncol 2007 Oct 10;25(29):4569-74 PMID: 17876008 09/19/2007       159 Citations
  • New agents, new rashes: an update on skin complications from cancer chemotherapy. (Patiyil S, Chan SN, Jatoi A) Curr Oncol Rep 2006 Jul;8(4):269-74 PMID: 17254526 01/27/2007       2 Citations
  • Metastatic colorectal cancer: Therapeutic options. (Patiyil S, Alberts SR) Curr Treat Options Oncol 2006 Sep;7(5):389-98 PMID: 16904056 08/15/2006       7 Citations
  • Last update: 04/01/2016
    jenkins-FCD Prod-300 626508253d14e4184314fb9f66322a03a5906796